Real-World data hunt for better cancer drug sequence

This study looked back at the medical records of 818 adults in the U.S. with advanced colorectal cancer that had spread. Researchers wanted to understand if taking the drug regorafenib first, followed by TAS-102 (with or without bevacizumab), or the reverse order, led to better real-world results. The goal was to gather knowledge from routine patient care to help doctors make better treatment sequence decisions, as both drugs are already approved but the best order is unclear.